Ischemic StrokeRISE-UPNCT04130503
The Recovery in Stroke Using PAP Study
A study testing PAP and HLE in people with Ischemic Stroke and Obstructive Sleep Apnea, run by Yale University at 1 site in United States.
Trial summary
The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke, Obstructive Sleep Apnea
- What is being tested?
- PAP and HLE
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 360 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2019to Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Having an acute ischemic stroke with brain imaging within 48 hours of symptoms onset;
- Being within 5 days of neurologic symptoms onset;
- Moderate (15 =< overall AHI < 30) /severe (overall AHI >= 30) OSA, thus with an obstructive apnea-hypopnea index AHI >= 15.
Who cannot join
- Past use of prescribed PAP for OSA;
- Suspected sleep disorder other than OSA (e.g., narcolepsy) (because such patients should be referred for a formal PSG in a sleep laboratory);
- Life expectancy is less than 6 months (e.g., hospice patients);
- Patients who require mechanical ventilation (because such patients could not participate in the intervention protocol);
- Non-English language patients (because the intervention strategy involves forming a relationship between the patient and research staff);
- Central sleep apnea with > 50% of respiratory events classified as central apnea;
- Resting oxygen saturation < 90%.
- Inability to provide their own informed consent. To enhance the generalizability of our study, all stroke severity will be included. However, we will exclude patients who cannot provide their own consent. This is because patients will need to participate actively in the protocol with a behavioral intervention. An assessment of the patient's competence to provide consent will be made based on published recommendations.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Yale University
New Haven, Connecticut, 06519
Klar Yaggi, MD, 203-209-4274, henry.yaggi@yale.edu
About this study
The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.
Read the detailed description
This study has 4 aims: 3 main aims and an additional exploratory aim.
Specific aim 1 or Aim A: Test whether PAP treatment for OSA in ischemic stroke improves stroke severity, post-stroke symptoms, post-stroke functional recovery (primary outcome), and quality of life.
Specific aim 2 or Aim D: Determine whether acute vs. subacute initiation of PAP in ischemic stroke results in greater improvement in post-stroke outcomes (stroke severity, symptoms, stroke recovery, quality of life).
Specific Aim 3 or Aim B: Conduct in-depth qualitative interviews with 25-30 stroke patients, family members, and acute care providers to elicit their experience with PAP use, including factors that influence adherence.
Exploratory aim or Aim C: Evaluate whether polysomnographic measures have prognostic utility in understanding the variability in stroke recovery.
With regard to projected recruitment scenarios, investigators will use an appropriate Aim scenario as described below:
In case of low post-randomization losses with symmetrical distribution between mild and no OSA/SAS (sleep apnea syndrome) and more severe OSA/SAS - Aims labeled with numbers will be used.
In case of high post randomization losses with asymmetrical distribution between mild and no OSA/SAS (sleep apnea syndrome) and more severe OSA/SAS - the same Aims labeled with letters will be used.
- Conditions
- Ischemic Stroke, Obstructive Sleep Apnea
- Being tested
- PAP, HLE
- Medical subject headings
- Ischemic Stroke, Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PAPDevice
Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
HLEBehavioural
All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
| Study group | Role | What they receive |
|---|---|---|
| PAP treatment- Acute | Experimental | Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. Receives: Device: PAP; Behavioral: HLE |
| Usual Care (HLE) | Active comparator | All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. Receives: Behavioral: HLE |
| PAP treatment- Subacute | Experimental | Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. Receives: Device: PAP; Behavioral: HLE |
| Exploratory arm | Other | Non-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) <15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI. Receives: Behavioral: HLE |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale (mRS)
The Modified Rankin Scale is a widely used measure of functional status and is sensitive to the full range of impairment from mild to severe. This objective examination scale with be video recorded by field staff and subsequently scored by the study neurologist blinded to randomization arm. The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 6. The higher the score, the more severe the disability. A score of 6 indicates the patient has expired (during the hospital stay or after discharge from the hospital).
Measured: 6 months
Change in Katz Scale
The Katz Index of Independence in Activities of Daily Living (KatzADL), is the most appropriate instrument to assess functional status as a measurement of the client's ability to perform Activities of Daily Living independently.
The Index ranks adequacy of performance in the 6 functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the 6 functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment
Measured: Randomization date, 3 months, 6 months
Secondary outcomes (17)
NIH Stroke Scale (NIHSS)
Stroke severity will be measured using the NIHSS. The NIHSS is a 15-item objective neurological examination scale. This scale has been used extensively to evaluate stroke severity and is a strong predictor of post-stroke outcomes. This exam will be video recorded by field staff and subsequently scored by the study neurologist blinded to randomization arm. Ratings for each item are scored on a 3- to 5-point scale, with 0 as normal, and there is an allowance for untestable items. Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as follows: Very Severe: >25, Severe: 15 - 24, Mild to Moderately Severe: 5 - 14, Mild: 1 - 5.
Measured: 1 month
NIH Stroke Scale (NIHSS)
Stroke severity will be measured using the NIHSS. The NIHSS is a 15-item objective neurological examination scale. This scale has been used extensively to evaluate stroke severity and is a strong predictor of post-stroke outcomes. This exam will be video recorded by field staff and subsequently scored by the study neurologist blinded to randomization arm. Ratings for each item are scored on a 3- to 5-point scale, with 0 as normal, and there is an allowance for untestable items. Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as follows: Very Severe: >25, Severe: 15 - 24, Mild to Moderately Severe: 5 - 14, Mild: 1 - 5.
Measured: 3 months
Epworth Sleepiness Scale (ESS)
The ESS asks: How likely are you to doze off or fall asleep in the following situations? The 8-item questionnaire uses a 3-point Likert scale where 0 equals never doze, and 3 equals high chance of dozing. The ESS is widely used in studies of sleep apnea and is considered a standard measure of daytime sleepiness.
Measured: 6 months
Medical Outcomes Survey-Short Form 36 (MOS-SF36)
The 36-Item Short Form Survey (SF-36) is an outcome measure instrument that is often used, well-researched, self-reported measure of health. It stems from a study called the Medical Outcomes Study for the objective measure of the quality of life.
It comprises 36 questions that cover eight domains of health:
- Limitations in physical activities because of health problems.
- Limitations in social activities because of physical or emotional problems
- Limitations in usual role activities because of physical health problems
- Bodily pain
- General mental health (psychological distress and well-being)
- Limitations in usual role activities because of emotional problems
- Vitality (energy and fatigue)
- General health perceptions The SF-36 is often used as a measure of a person or population's quality of life (QOL).
Measured: 6 months
Patient Health Questionnaire-8 (PHQ-8)
The PHQ-8 will provide a psychometrically valid measure of depression, a common concern in post-stroke and OSA patients, and an attribute which has been reported to improve with PAP therapy. The PHQ-8 is an 8-item assessment. Each item is scored on a Likert scale in which "0" (not at all) to "3" (nearly every day) with maximum total score of 24. Higher score signifies increase in severity. These questions are asked based on the past 2 weeks.
Measured: 6 months
Montreal Cognitive Assessment (MoCA)
The MoCA was designed as a rapid screening instrument for cognitive dysfunction. It assesses different cognitive domains such as attention and concentration, executive functions, memory, language, visual-constructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.
Measured: 6 months
Stroke Specific Quality of Life (SS-QOL)
The SS-QOL is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Scale domains and items were derived from a series of interviews with post- stroke patients. It takes approximately 10-15 minutes to complete the SS-QOL scale. Higher scores indicate better functioning. The SS-QOL yields both domain scores and an overall SS- QOL summary score. The domain scores are unweighted averages of the associated items while the summary score is an unweighted average of all twelve domain scores.
Measured: 6 months
The Calgary Sleep Apnea Quality of Life Index (SAQLI)
The SAQLI is designed to assess responsiveness to OSA treatment and will be administered to obtain a measure of OSA-disease specific quality of life. Disease-specific health-related 84-item quality of life questionnaire for adults with sleep apnea; designed to measure outcome of sleep apnea treatment. It assesses four functional domains plus a fifth domain assessing the negative impacts of therapeutic intervention. (A) Daily functioning (11 items), (B) Social interactions (13 items), (C) Emotional functioning (11 items), (D) Symptoms (21 items; select 5 symptoms), (E) Treatment-related symptoms (26 items; select 5 symptoms), (F) Impact (2 items) Domains A-D: 7-point Likert scale, sum divided by total number of questions answered, Domain E: 7-point Likert scale, mean divided by 5, Domains A-D and E are further modified by a weighting score, derived from responses to Section F (10-point Likert scale). Lower scores indicate greater severity.
Measured: 6 months
Formative Adherence Evaluation
For patients with sleep apnea, qualitative, in-depth interviews with approximately n=25 patients and their bedpartners (dyads) purposefully sampled based on demographics, adherence, and treatment arm. Interviews of the dyads will occur at approximately 3 months into the study when PAP adherence patterns have been established.
Measured: 3 months
Change in Berg Balance Scale
The Berg Balance Scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14-item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete.
Though initial recruitment of the RISE-UP study occurs in the hospital, the setting for most of the study follow-up may occur in the home and rehabilitation settings and can be done remotely (for example over the phone). *- when follow-up is performed over the phone this assessment can be excluded
Measured: 3 and 6 months
Fall Events
Falls are identified and recorded as a part of the routine adverse event collection and reporting protocol. In addition to identification of a fall event, reasons for the fall, and location of the fall, follow-up care will be identified through interview questions and chart review. Individuals who sustained at least one fall were considered a -faller- for these analyses. The fall event information will be categorized for these analyses to describe both the circumstances and the consequences of falls.
Measured: Up to 6 months
Change in Pittsburgh Sleep Quality Index (PSQI)
Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Each of the questionnaire's 19 self-reported items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Five additional questions rated by the respondent's roommate or bed partner are included for clinical purposes and are not scored.
Scores for each question range from 0 to 3, with higher scores indicating more acute sleep disturbances.
Measured: Randomization date, 3 months, 6 months
Change in Insomnia Severity Index (ISI) Severity Index
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. The usual recall period is the "last month" and the dimensions evaluated are: severity of sleep onset, sleep maintenance, and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Measured: Randomization date, 3 months, 6 months
Change in PROMIS Pain Interference - Short Form 6b V1.0
The Patient-Reported Outcomes Measurement Information System (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well-being from the patient perspective. PROMIS measures are standardized, allowing for assessment of many patient-reported outcome domains-including pain, fatigue, emotional distress, physical functioning and social role participation-based on common metrics that allow for comparisons across domains, across chronic diseases, and with the general population. 6-items measure assessing self-reported perceptions of impairment due to pain interference. Response options range from 1=Not at all to 5=Very much. Responses are summed to create a raw score with higher scores indicating greater impairment
Measured: Randomization date, 3 months, 6 months
Change in PROMIS Pain Intensity - Short Form 3a V1.0
The Patient-Reported Outcomes Measurement Information System (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well-being from the patient perspective. PROMIS measures are standardized, allowing for assessment of many patient-reported outcome domains-including pain, fatigue, emotional distress, physical functioning and social role participation-based on common metrics that allow for comparisons across domains, across chronic diseases, and with the general population. 3-items measure assessing self-reported perceptions of impairment due to pain intensity. Response options range from 1=Not at all to 5=Very much. Responses are summed to create a raw score with higher scores indicating greater impairment
Measured: Randomization date, 3 months, 6 months
Change in PROMIS Short Form v1.0 Sleep Disturbance 8a
The Patient-Reported Outcomes Measurement Information System (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well-being from the patient perspective. PROMIS measures are standardized, allowing for assessment of many patient-reported outcome domains-including pain, fatigue, emotional distress, physical functioning and social role participation-based on common metrics that allow for comparisons across domains, across chronic diseases, and with the general population. 8-items assessing self-reported perceptions of impairment due sleep disturbance. Response options range from 1=Not at all to 5=Very much. Participants will be asked about the last 7 days. Responses are summed to create a raw score with higher scores indicating greater impairment.
Measured: day 7
Change in PROMIS Short Form v1.0 Sleep-Related Impairment 8a
The Patient-Reported Outcomes Measurement Information System (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well-being from the patient perspective. PROMIS measures are standardized, allowing for assessment of many patient-reported outcome domains-including pain, fatigue, emotional distress, physical functioning and social role participation-based on common metrics that allow for comparisons across domains, across chronic diseases, and with the general population. 8-items assessing self-reported perceptions of impairment due to sleep problems. Response options range from 1=Not at all to 5=Very much. Participants will be asked about the last 7 days. Responses are summed to create a raw score with higher scores indicating greater impairment.
Measured: day 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2019
- Study start1 Sep 2019
- Primary completionOct 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized to usual care or PAP- acute and subacute patients will receive different PAP treatments (non-randomized).
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- Hartford HealthCare, National Institute of Nursing Research (NINR), American Academy of Sleep Medicine Foundation (AASM)
- Responsible party
- Sponsor
- Investigators
- Klar Yaggi, MD, MPH, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04130503
- Sponsor's protocol ID
- 2000024512
- Other IDs
- 1R01NR018335-01
- Acronym
- RISE-UP
- Status last verified
- Aug 2025
- First submitted
- 16 Oct 2019
- Last updated
- 5 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Recovery in Stroke Using PAP Study
- ClinicalTrials.gov ID
- NCT04130503
- Acronym / sponsor ID
- RISE-UP / 2000024512
- Conditions
- Ischemic Stroke, Obstructive Sleep Apnea
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- Hartford HealthCare, National Institute of Nursing Research (NINR), American Academy of Sleep Medicine Foundation (AASM)
- Study start
- 1 Sep 2019 (actual)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 17 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.
Detailed description
This study has 4 aims: 3 main aims and an additional exploratory aim.
Specific aim 1 or Aim A: Test whether PAP treatment for OSA in ischemic stroke improves stroke severity, post-stroke symptoms, post-stroke functional recovery (primary outcome), and quality of life.
Specific aim 2 or Aim D: Determine whether acute vs. subacute initiation of PAP in ischemic stroke results in greater improvement in post-stroke outcomes (stroke severity, symptoms, stroke recovery, quality of life).
Specific Aim 3 or Aim B: Conduct in-depth qualitative interviews with 25-30 stroke patients, family members, and acute care providers to elicit their experience with PAP use, including factors that influence adherence.
Exploratory aim or Aim C: Evaluate whether polysomnographic measures have prognostic utility in understanding the variability in stroke recovery.
With regard to projected recruitment scenarios, investigators will use an appropriate Aim scenario as described below:
In case of low post-randomization losses with symmetrical distribution between mild and no OSA/SAS (sleep apnea syndrome) and more severe OSA/SAS - Aims labeled with numbers will be used.
In case of high post randomization losses with asymmetrical distribution between mild and no OSA/SAS (sleep apnea syndrome) and more severe OSA/SAS - the same Aims labeled with letters will be used.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Participants will be randomized to usual care or PAP- acute and subacute patients will receive different PAP treatments (non-randomized).
| Arm | Type | Receives |
|---|---|---|
| PAP treatment- Acute | Experimental | Device: PAP, Behavioral: HLEAcute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. |
| Usual Care (HLE) | Active comparator | Behavioral: HLEAll patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. |
| PAP treatment- Subacute | Experimental | Device: PAP, Behavioral: HLEAcute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur. |
| Exploratory arm | Other | Behavioral: HLENon-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) <15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Having an acute ischemic stroke with brain imaging within 48 hours of symptoms onset;
- Being within 5 days of neurologic symptoms onset;
- Moderate (15 =< overall AHI < 30) /severe (overall AHI >= 30) OSA, thus with an obstructive apnea-hypopnea index AHI >= 15.
Key exclusion criteria (8 listed)
- Past use of prescribed PAP for OSA;
- Suspected sleep disorder other than OSA (e.g., narcolepsy) (because such patients should be referred for a formal PSG in a sleep laboratory);
- Life expectancy is less than 6 months (e.g., hospice patients);
- Patients who require mechanical ventilation (because such patients could not participate in the intervention protocol);
- Non-English language patients (because the intervention strategy involves forming a relationship between the patient and research staff);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PAPPositive airway pressure (PAP) treatment of obstructive sleep apnea (OSA). | Device | PAP treatment- Acute, PAP treatment- Subacute |
| HLEAll patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention. | Behavioural | Exploratory arm, PAP treatment- Acute, PAP treatment- Subacute, Usual Care (HLE) |
Primary outcome
Modified Rankin Scale (mRS)
Time frame: 6 months
The Modified Rankin Scale is a widely used measure of functional status and is sensitive to the full range of impairment from mild to severe. This objective examination scale with be video recorded by field staff and subsequently scored by the study neurologist blinded to randomization arm. The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 6. The higher the score, the more severe the disability. A score of 6 indicates the patient has expired (during the hospital stay or after discharge from the hospital).
Change in Katz Scale
Time frame: Randomization date, 3 months, 6 months
The Katz Index of Independence in Activities of Daily Living (KatzADL), is the most appropriate instrument to assess functional status as a measurement of the client's ability to perform Activities of Daily Living independently. The Index ranks adequacy of performance in the 6 functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the 6 functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment
17 secondary outcomes
NIH Stroke Scale (NIHSS)
Time frame: 1 month
NIH Stroke Scale (NIHSS)
Time frame: 3 months
Epworth Sleepiness Scale (ESS)
Time frame: 6 months
Medical Outcomes Survey-Short Form 36 (MOS-SF36)
Time frame: 6 months
Patient Health Questionnaire-8 (PHQ-8)
Time frame: 6 months
Montreal Cognitive Assessment (MoCA)
Time frame: 6 months
Stroke Specific Quality of Life (SS-QOL)
Time frame: 6 months
The Calgary Sleep Apnea Quality of Life Index (SAQLI)
Time frame: 6 months
Formative Adherence Evaluation
Time frame: 3 months
Change in Berg Balance Scale
Time frame: 3 and 6 months
Fall Events
Time frame: Up to 6 months
Change in Pittsburgh Sleep Quality Index (PSQI)
Time frame: Randomization date, 3 months, 6 months
Change in Insomnia Severity Index (ISI) Severity Index
Time frame: Randomization date, 3 months, 6 months
Change in PROMIS Pain Interference - Short Form 6b V1.0
Time frame: Randomization date, 3 months, 6 months
Change in PROMIS Pain Intensity - Short Form 3a V1.0
Time frame: Randomization date, 3 months, 6 months
Change in PROMIS Short Form v1.0 Sleep Disturbance 8a
Time frame: day 7
Change in PROMIS Short Form v1.0 Sleep-Related Impairment 8a
Time frame: day 7
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Not yet recruiting
Accelerated Theta-Burst Stimulation for Refractory Central Post-Stroke Pain
Central Post-Stroke Pain, Stroke
RecruitingPhase 3
Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
Ischemic Stroke, TIA
Not yet recruitingPhase 4
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Ischemic Stroke
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Recruiting
Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory
Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Klar Yaggi, MD, MPH principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PAP and HLE in people with Ischemic Stroke and Obstructive Sleep Apnea, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Radu Radulescu, MD (2033614037, radu.radulescu@yale.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale (mRS) (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025; AzTrials last refreshed its copy on 2 Nov 2026.